A novel recombinant human thrombopoietin for treating prolonged isolated thrombocytopenia after allogeneic stem cell transplantation
Sign Up to like & getrecommendations! Published in 2018 at "Platelets"
DOI: 10.1080/09537104.2018.1557613
Abstract: Abstract Patients with prolonged isolated thrombocytopenia (PT) after allogeneic stem cell transplantation (allo-SCT) are known to have a poor prognosis. However, there is no standard treatment for PT. The present study aimed to investigate the… read more here.
Keywords: response; treatment; prolonged isolated; thrombocytopenia allogeneic ... See more keywords
TPO versus TPO: the good, the bad, and the to be determined
Sign Up to like & getrecommendations! Published in 2021 at "British Journal of Haematology"
DOI: 10.1111/bjh.17825
Abstract: The first-generation thrombopoietic agents, recombinant human thrombopoietin (rhTPO) and pegylated human recombinant megakaryocyte growth and development factor (PEG-rHuMGDF), were developed following identification and cloning of human thrombopoietin (TPO) in 1994. Unfortunately, formation of cross-reactive antibodies… read more here.
Keywords: platelet count; hematology; group; rhtpo ... See more keywords
Recombinant Human Thrombopoietin in the Treatment of Chemotherapy-Induced Thrombocytopenia in Acute Myeloid Leukemia
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-141328
Abstract: Objective: To investigate the efficacy and safety of recombinant human thrombopoietin(rhTPO) in the treatment of thrombocytopenia after chemotherapy for acute myeloid leukemia in vivo and in vitro. Methods: A retrospective collection of 95 patients with… read more here.
Keywords: chemotherapy; myeloid leukemia; acute myeloid; rhtpo ... See more keywords
Cost-effectiveness analysis of rhTPO and rhIL-11 in the treatment of chemotherapy-induced thrombocytopenia in hematological tumors based on real-world data.
Sign Up to like & getrecommendations! Published in 2022 at "Annals of palliative medicine"
DOI: 10.21037/apm-22-880
Abstract: BACKGROUND Chemotherapy-induced thrombocytopenia (CIT) is a common adverse reaction to chemotherapy that can lead to treatment delay, platelet transfusion, thereby increasing treatment costs, reducing chemotherapy effectiveness and affecting prognosis. Based on real-world data, this study… read more here.
Keywords: cost; rhil; effectiveness; platelet ... See more keywords
Administration of recombinant human thrombopoietin is associated with alleviated thrombocytopenia in adult intensive care unit patients with pneumonia: A single-center retrospective study
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2022.1007719
Abstract: Background: Recombinant human thrombopoietin (rhTPO) is reported to stimulate platelet production and increase peripheral platelet counts; it is primarily used to manage chemotherapy-induced thrombocytopenia and idiopathic thrombocytopenic purpura. However, the effect of rhTPO in patients… read more here.
Keywords: patients pneumonia; rhtpo; platelet; study ... See more keywords